Shanghai Labway Clinical Laboratory (301060.SZ) shareholder Hailan Group plans to reduce its shareholding by no more than 2%.
Lanwei Medical (301060.SZ) announced that its shareholder Hailan Group Co., Ltd. (referred to as "Hailan Group") plans to...
Announcement from Shanghai Labway Clinical Laboratory (301060.SZ): The company's shareholder, Hailan Group Limited (referred to as "Hailan Group"), plans to reduce its holdings of the company's shares by no more than 7.9704 million shares (representing 2.00% of the total share capital excluding shares held in the company's repurchase special account) through centralized bidding and/or block trading within 3 months after 15 trading days from the disclosure of this reduction plan.
Related Articles
FAST RETAIL-DRS (06288) will resume trading on July 11th.
Essence of Securities Morning Meeting | Focus on industries expected to reverse under the "anti-internal competition" policy.
From price rebound to supply-side reconstruction, CITIC Securities analyzes the way out of breaking the deadlock of "anti-internal competition" in the photovoltaic industry.
FAST RETAIL-DRS (06288) will resume trading on July 11th.
Essence of Securities Morning Meeting | Focus on industries expected to reverse under the "anti-internal competition" policy.
From price rebound to supply-side reconstruction, CITIC Securities analyzes the way out of breaking the deadlock of "anti-internal competition" in the photovoltaic industry.
